Ursula Wiedermann

Last updated

Ursula Wiedermann (born 5 August 1965) [1] is an Austrian medical scientist who has made significant contributions in the field of allergies and of cancer immunotherapy. She is currently Professor of Vaccinology at the Medical University of Vienna. Wiedermann's work in the field of B cell peptide vaccines led to the creation of HER-Vaxx, an immunotherapy for the treatment of HER-2-positive cancers. This vaccine is currently being taken into mid-stage clinical development in gastric cancer by the biotech company Imugene, where Wiedermann is Chief Scientific Officer.

Contents

Background

After obtaining an MD degree from the Medical University of Vienna, Wiedermann gained a PhD in Immunology at the University of Gothenburg in Sweden, where the focus of her PhD work was mucosal immunity and vaccination. After returning to the Medical University of Vienna Wiedermann researched mucosal vaccination against allergic diseases and later began to look at vaccine development against infectious diseases and tumours as well as explore the issues of immune responsiveness and immune failures upon vaccination. Wiedermann became head of Vienna's Institute of Specific Prophylaxis and Tropical Medicine in 2004 and was named Professor of Vaccinology in 2006. [2]

Allergy research

A theme of Wiedermann's allergy research has been the treatment of allergies via mucosal tolerance induction with recombinant allergens, [3] probiotics or other microbes. For a key 2001 paper in the International Archives of Allergy and Immunology Wiedermann used recombinant fragments of the birch pollen allergen Bet v I to induce mucosal tolerance in a mouse model of birch pollen allergy. [4] In 2008 the Wiedermann lab challenged the 'microflora hypothesis', which holds that altered microflora contributed to allergies, by showing that Bet v 1 could induce mucosal tolerance in mice regardless of the presence or absence of microflora. [5] In 2009 the Wiedermann lab provided some supporting evidence for the hygiene hypothesis of allergies by showing that infection with the intracellular parasite Toxoplasma gondii could prevent allergic immune responses in birch pollen allergic mice. [6] In 2011 the Wiedermann lab showed in mice that probiotics could have anti-allergic effects against multiple allergens. [7] In 2012 the Wiedermann lab showed that a fusion protein containing several allergens could treat birch pollen-related food allergy, in which patients are allergic to homologues of Bet v I. [8] Also in 2012 the Wiedermann lab showed in mice that perinatal administration of Lactobacillus paracasei to pregnant and lactating mothers could protect against the development of airway inflammation in offspring. [9]

Cancer immunotherapy research

Beginning around 2004 Wiedermann began to working on the technology that evolved into HER-Vaxx, a B cell peptide cancer immunotherapy that could induce an antibody response targeting HER-2 overexpressing tumours. Following on from favourable pre-clinical data, [10] Wiedermann et al. ran a small 10-patient safety study of HER-Vaxx in ten patients with Stage IV metastatic breast cancer, albeit with low HER-2 expression. This study found the vaccine to be safe, with no observed cardiotoxicity. The patients developed anti-HER-2 antibodies and in vitro, those anti-HER-2 antibodies showed potent anti-tumour activity. Also in vitro, blood from the patients carried markers of a cellular immune response such as IL-2, IFN-γ and TNF-α (meaning that ultimately patients could be expected to develop T cells to kill the cancer cells, and not just antibodies). The vaccine took down the ‘T reg’ cell count in the patients, potentially indicating an overcoming of the cancer’s immunoresistance. [11] In 2012 a start-up company called Biolife Science was incorporated to develop this immunotherapy. Early-stage funding was secured from Australian and US investors in 2013, after which Biolife was taken public in December 2013 in a reverse takeover of an Australian drug development company called Imugene, whose name was retained after the merger. Wiedermann joined Imugene's Scientific Advisory Board in January 2014 [12] and was named Chief Scientific Officer of Imugene in June 2015. [13]

Related Research Articles

<span class="mw-page-title-main">Antigen</span> Molecule triggering an immune response (antibody production) in the host

In immunology, an antigen (Ag) is a molecule, moiety, foreign particulate matter, or an allergen, such as pollen, that can bind to a specific antibody or T-cell receptor. The presence of antigens in the body may trigger an immune response.

<span class="mw-page-title-main">Allergy</span> Immune system response to a substance that most people tolerate well

Allergies, also known as allergic diseases, are various conditions caused by hypersensitivity of the immune system to typically harmless substances in the environment. These diseases include hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis. Symptoms may include red eyes, an itchy rash, sneezing, coughing, a runny nose, shortness of breath, or swelling. Note that food intolerances and food poisoning are separate conditions.

An allergen is an otherwise harmless substance that triggers an allergic reaction in sensitive individuals by stimulating an immune response.

Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer.

<span class="mw-page-title-main">Allergic rhinitis</span> Nasal inflammation due to allergens in the air

Allergic rhinitis, of which the seasonal type is called hay fever, is a type of inflammation in the nose that occurs when the immune system overreacts to allergens in the air. It is classified as a type I hypersensitivity reaction. Signs and symptoms include a runny or stuffy nose, sneezing, red, itchy, and watery eyes, and swelling around the eyes. The fluid from the nose is usually clear. Symptom onset is often within minutes following allergen exposure, and can affect sleep and the ability to work or study. Some people may develop symptoms only during specific times of the year, often as a result of pollen exposure. Many people with allergic rhinitis also have asthma, allergic conjunctivitis, or atopic dermatitis.

<span class="mw-page-title-main">Allergic conjunctivitis</span> Medical condition

Allergic conjunctivitis (AC) is inflammation of the conjunctiva due to allergy. Although allergens differ among patients, the most common cause is hay fever. Symptoms consist of redness, edema (swelling) of the conjunctiva, itching, and increased lacrimation. If this is combined with rhinitis, the condition is termed allergic rhinoconjunctivitis (ARC).

<span class="mw-page-title-main">Allergen immunotherapy</span> Medical treatment for environmental allergies

Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for environmental allergies and asthma. Immunotherapy involves exposing people to larger and larger amounts of allergens in an attempt to change the immune system's response.

Oral allergy syndrome (OAS) or pollen-food allergy syndrome (PFAS) is a type of allergy classified by a cluster of allergic reactions in the mouth and throat in response to eating certain fruits, nuts, and vegetables. It typically develops in adults with hay fever. It is not usually serious.

Immune tolerance, also known as immunological tolerance or immunotolerance, refers to the immune system's state of unresponsiveness to substances or tissues that would otherwise trigger an immune response. It arises from prior exposure to a specific antigen and contrasts the immune system's conventional role in eliminating foreign antigens. Depending on the site of induction, tolerance is categorized as either central tolerance, occurring in the thymus and bone marrow, or peripheral tolerance, taking place in other tissues and lymph nodes. Although the mechanisms establishing central and peripheral tolerance differ, their outcomes are analogous, ensuring immune system modulation.

Allergies to cats, a type of animal allergy, are one of the most common allergies experienced by humans. Among the eight known cat allergens, the most prominent allergen is secretoglobin Fel d 1, which is produced in the anal glands, salivary glands, and, mainly, in sebaceous glands of cats, and is ubiquitous in the United States, even in households without cats. The second most common is Fel d 2, this type is triggered by the cats dead skin flakes (dander) that are floating in the air as well as in the smell of cat urine.

<span class="mw-page-title-main">Egg allergy</span> Type of food allergy caused by eggs

Egg allergy is an immune hypersensitivity to proteins found in chicken eggs, and possibly goose, duck, or turkey eggs. Symptoms can be either rapid or gradual in onset. The latter can take hours to days to appear. The former may include anaphylaxis, a potentially life-threatening condition which requires treatment with epinephrine. Other presentations may include atopic dermatitis or inflammation of the esophagus.

ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy (AIT) products for the prevention and treatment of allergy. It is one of the world's largest makers of allergy immunotherapy products with 67% of its revenue coming from sales in Europe.

The following outline is provided as an overview of and topical guide to immunology:

<span class="mw-page-title-main">Mucosal immunology</span> Field of study

Mucosal immunology is the study of immune system responses that occur at mucosal membranes of the intestines, the urogenital tract, and the respiratory system. The mucous membranes are in constant contact with microorganisms, food, and inhaled antigens. In healthy states, the mucosal immune system protects the organism against infectious pathogens and maintains a tolerance towards non-harmful commensal microbes and benign environmental substances. Disruption of this balance between tolerance and deprivation of pathogens can lead to pathological conditions such as food allergies, irritable bowel syndrome, susceptibility to infections, and more.

Peptide-based synthetic vaccines are subunit vaccines made from peptides. The peptides mimic the epitopes of the antigen that triggers direct or potent immune responses. Peptide vaccines can not only induce protection against infectious pathogens and non-infectious diseases but also be utilized as therapeutic cancer vaccines, where peptides from tumor-associated antigens are used to induce an effective anti-tumor T-cell response.

<span class="mw-page-title-main">William Frankland (allergist)</span> British allergist and immunologist (1912–2020)

Alfred William "Bill" Frankland MBE was a British allergist and immunologist whose achievements included the popularisation of the pollen count as a piece of weather-related information to the British public, speculation regarding the effects of overly sterile living environments, and the prediction of increased levels of allergy to penicillin. He continued to work for a number of years after turning 100.

Cross-reactive carbohydrate determinants (CCDs) play a role in the context of allergy diagnosis. The terms CCD or CCDs describe protein-linked carbohydrate structures responsible for the phenomenon of cross-reactivity of sera from allergic patients towards a wide range of allergens from plants and insects. In serum-based allergy diagnosis, antibodies of the IgE class directed against CCDs therefore give the impression of polysensitization. Anti-CCD IgE, however, does not seem to elicit clinical symptoms. Diagnostic results caused by CCDs are therefore regarded as false positives.

Imugene Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Imugene's unique platform technologies seeks to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

CRM197 is a non-toxic mutant of diphtheria toxin, currently used as a carrier protein for polysaccharides and haptens to make them immunogenic. There is some dispute about the toxicity of CRM197, with evidence that it is toxic to yeast cells and some mammalian cell lines.

<span class="mw-page-title-main">HAL Allergy Group</span>

HAL Allergy Group is a pharmaceutical company that develops, produces and sells products for allergy diagnostic and allergen immunotherapy (AIT). The research facilities and headquarters are located at the Leiden Bio Science Park, Netherlands.

References

  1. ↑ "Univ. Prof. Dr. Ursula WIEDERMANN, MD, MSc, PhD" (PDF). Medical University of Vienna Researcher Profiles. Retrieved 25 April 2022.
  2. ↑ "PhD Program, Molecular, Cellular and Clinical Allergology". Phd-mcca.at. Retrieved 3 December 2015.
  3. ↑ Wiedermann U. (October 1, 2005). "Prophylaxis and therapy of allergy by mucosal tolerance induction with recombinant allergens or allergen constructs". Curr Drug Targets Inflamm Allergy. 4 (5): 577–83. doi:10.2174/156801005774322207. PMID   16248826.
  4. ↑ Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D. (November 1, 2007). "Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice". Int Arch Allergy Immunol. 126 (1): 68–77. doi:10.1159/000049496. PMID   11641608. S2CID   12838287.
  5. ↑ Repa A; Kozakova H; Hudcovic T; Stepankova R; Hrncir T; Tlaskalova-Hogenova H; Pollak A; Wiedermann U. (April 15, 2008). "Susceptibility to nasal and oral tolerance induction to the major birch pollen allergen Bet v 1 is not dependent on the presence of the microflora". Immunol. Lett. 117 (1): 50–56. doi:10.1016/j.imlet.2007.11.025. PMID   18241932.
  6. ↑ Wagner A; Förster-Waldl E; Garner-Spitzer E; Schabussova I; Kundi M; Pollak A; Scheiner O; Joachim A; Wiedermann U. (March 1, 2009). "Immunoregulation by Toxoplasma gondii infection prevents allergic immune responses in mice". Int J Parasitol. 39 (4): 465–72. doi:10.1016/j.ijpara.2008.09.003. PMID   18938169.
  7. ↑ Schabussova I; Hufnagl K; Wild C; Nutten S; Zuercher AW; Mercenier A; Wiedermann U. (February 24, 2011). "Distinctive anti-allergy properties of two probiotic bacterial strains in a mouse model of allergic poly-sensitization". Vaccine. 29 (10): 1981–90. doi:10.1016/j.vaccine.2010.12.101. PMID   21216308.
  8. ↑ Hoflehner E; Hufnagl K; Schabussova I; Jasinska J; Hoffmann-Sommergruber K; Bohle B; Maizels RM; Wiedermann U. (June 29, 2012). "Prevention of birch pollen-related food allergy by mucosal treatment with multi-allergen-chimers in mice". PLOS ONE. 7 (6): e39409. Bibcode:2012PLoSO...739409H. doi: 10.1371/journal.pone.0039409 . PMC   3387141 . PMID   22768077.
  9. ↑ Schabussova I1, Hufnagl K, Tang ML, Hoflehner E, Wagner A, Loupal G, Nutten S, Zuercher A, Mercenier A, Wiedermann U. (June 29, 2012). "Perinatal maternal administration of Lactobacillus paracasei NCC 2461 prevents allergic inflammation in a mouse model of birch pollen allergy". PLOS ONE. 7 (7): e40271. Bibcode:2012PLoSO...740271S. doi: 10.1371/journal.pone.0040271 . PMC   3391241 . PMID   22792257.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
  10. ↑ Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U. (November 1, 2007). "Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice". Breast Cancer Res Treat. 106 (1): 29–38. doi:10.1007/s10549-006-9469-4. PMID   17203384. S2CID   23211112.
  11. ↑ Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC. (February 1, 2010). "A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study". Breast Cancer Res Treat. 119 (3): 673–83. doi:10.1007/s10549-009-0666-9. PMID   20092022. S2CID   9570606.
  12. ↑ "Imugene Appoints Distinguished Scientists to Scientific Advisory Board" (PDF). asx.com.au. 20 January 2014. Retrieved 3 December 2015.
  13. ↑ "Leading European Immunologist Prof Ursula Wiedermann Appointed Imugene Chief Scientific Officer". Imugene.com. 5 June 2015. Retrieved 3 December 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.